CD274 and neoplasm: Sintilimab, as a selective anti-PD-1 antibody,by inhibiting the interaction between PD-1 and its ligand PD-L1, effectively relieve the immunosuppressive effect of the body, and enhance the activity of T cells, thereby greatly enhancing the killing ability and immune surveillance ability of T cells on tumors, and inhibiting the proliferation of tumor cells [13].